Advertisement

Transition of Left Ventricular Ejection Fraction in Heart Failure

  • Yasuhiko Sakata
  • Kanako Tsuji
  • Kotaro Nochioka
  • Hiroaki ShimokawaEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1067)

Abstract

Along with a worldwide epidemiological transition and dramatic increase in the elderly population, both the incidence and prevalence of heart failure (HF) are increasing worldwide. This epidemic of HF is characterized by an increase of HF with preserved left ventricular ejection fraction (LVEF) (HFpEF) and a decrease of HF with reduced LVEF (HFrEF). Of note, transition between HFpEF and HFrEF has been recently highlighted, since it significantly relates with prognosis. Our recent studies indicated that temporary changes in LVEF are common and associated with prognosis in patients with HF. In this chapter, we summarize recent findings on temporal changes in LVEF and their prognostic impact in HF patients, acknowledging that further studies are needed to fully elucidate the pathophysiology of LVEF recovery and deterioration to improve clinical outcomes of HF patients, and also to develop therapies targeting novel pathways of myocardial recovery.

Keywords

Epidemiologic transition Heart failure Ischemic heart disease Left ventricular ejection fraction Prognosis 

References

  1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63:1123–1133CrossRefPubMedGoogle Scholar
  2. Amos AM, Jaber WA, Russell SD (2006) Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 152:509–513CrossRefPubMedGoogle Scholar
  3. Aurigemma GP, Zile MR, Gaasch WH (2006) Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 113:296–304CrossRefPubMedGoogle Scholar
  4. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC (2014) Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 129:2380–2387CrossRefPubMedPubMedCentralGoogle Scholar
  5. Benjamin EJ, Blaha MJ, Chiuve SE et al (2017) American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135:e146–e603CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JCM, Stricker BHC (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614–1619CrossRefPubMedGoogle Scholar
  7. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ (2005) Cardiomyocyte stiffness in diastolic heart failure. Circulation 111:774–781CrossRefPubMedGoogle Scholar
  8. Borlaug BA, Redfield MM (2011) Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123:2006–2013CrossRefPubMedPubMedCentralGoogle Scholar
  9. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM (2009) Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 54:410–148CrossRefPubMedPubMedCentralGoogle Scholar
  10. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL (2006) Systolic and diastolic heart failure in the community. JAMA 296:2209–2216CrossRefPubMedGoogle Scholar
  11. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, hernandez AF, Butler J, Yancy CW, Fonarow GC (2014) Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 168:721–730CrossRefPubMedGoogle Scholar
  12. Clarke CL, Grunwald GK, Allen LA, Barón AE, Peterson PN, Brand DW, Magid DJ, Masoudi FA (2013) Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 6:680–686CrossRefPubMedPubMedCentralGoogle Scholar
  13. Damasceno A, Mayosi BM, Sani M, Ogah OS, Mondo C, Ojji D, Dzudie A, Kouam CK, Suliman A, Schrueder N, Yonga G, Ba SA, Maru F, Alemayehu B, Edwards C, Davison BA, Cotter G, Sliwa K (2012) The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 172:1386–1394CrossRefPubMedGoogle Scholar
  14. de Groote P, Fertin M, Duva Pentiah A, Goeminne C, Lamblin N, Bauters C (2014) Long-term Dunlay functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy. Circ Heart Fail 7:434–439CrossRefPubMedGoogle Scholar
  15. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM (2012) Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5:720–726CrossRefPubMedPubMedCentralGoogle Scholar
  16. Gaasch WH, Delorey DE, Kueffer FJ, Zile MR (2009) Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. Am J Cardiol 104:1413–1415CrossRefPubMedGoogle Scholar
  17. Guo Y, Lip GY, Banerjee A (2013) Heart failure in East Asia. Curr Cardiol Rev 9:112–122CrossRefPubMedPubMedCentralGoogle Scholar
  18. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Pina IL, Trogdon JG (2013) American Heart Association advocacy coordinating committee; council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; council on clinical cardiology; council on epidemiology and prevention; stroke council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6:606–619CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hopper I, Samuel R, Hayward C, Tonkin A, Krum H (2014) Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis. J Card Fail 20:522–532CrossRefPubMedGoogle Scholar
  20. Hwang SJ, Melenovsky V, Borlaug BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63:2817–2827CrossRefPubMedGoogle Scholar
  21. Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC (2016) Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail 4:464–472CrossRefPubMedGoogle Scholar
  22. Kawaguchi M, Hay I, Fetics B, Kass DA (2003) Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 107:714–720CrossRefPubMedGoogle Scholar
  23. Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A (2013) Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol 168:1186–1194CrossRefPubMedGoogle Scholar
  24. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288:2144–2150CrossRefPubMedGoogle Scholar
  25. Komajda M, Lam CS (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35:1022–1032CrossRefGoogle Scholar
  26. Lam CS, Solomon SD (2014) The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail 16:1049–1055CrossRefPubMedGoogle Scholar
  27. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM (2007) Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115:1982–1990CrossRefPubMedPubMedCentralGoogle Scholar
  28. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR (2004) Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141:693–704CrossRefPubMedGoogle Scholar
  29. Maslowski AH, Nicholls MG, Ikram H, Espiner EA, Turner JG (1981) Haemodynamic, hormonal, and electrolyte responses to withdrawal of long-term captopril treatment for heart failure. Lancet 2:959–961CrossRefPubMedGoogle Scholar
  30. Massie BM, Nelson JJ, Lukas MA, Greenberg B, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA, COHERE Participant Physicians (2007) Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fraction in patients with heart failure in clinical practice. Am J Cardiol 99:1263–1268CrossRefPubMedGoogle Scholar
  31. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467CrossRefGoogle Scholar
  32. Moon J, Ko YG, Chung N, Ha JW, Kang SM, Choi EY, Rim SJ (2009) Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 25:e147–e150CrossRefPubMedPubMedCentralGoogle Scholar
  33. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H (1999) Can beta blocker therapy be withdrawn from patients with dilated cardiomyopathy. Am Heart J 138:456–459CrossRefPubMedGoogle Scholar
  34. Nadruz W Jr, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM (2016) Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 9:e002826CrossRefPubMedGoogle Scholar
  35. Naksuk N, Saab A, Li J-M, Florea V, Akkaya M, Anand IS, Benditt DG, Adabag S (2013) Incidence of appropriate shock in implantable cardioverter defibrillator patients with improved ejection fraction. J Card Fail 19:426–430CrossRefPubMedGoogle Scholar
  36. Omran AR (1971) The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q 49:509–538CrossRefPubMedGoogle Scholar
  37. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259. Suppl 1:S31–S35CrossRefPubMedGoogle Scholar
  38. Park JS, Kim JW, Seo KW, Choi BJ, Choi SY, Yoon MH, Hwang GS, Tahk SJ, Shin JH (2014) Recurrence of left ventricular dysfunction in patients with restored idiopathic dilated cardiomyopathy. Clin Cardiol 37:222–226CrossRefPubMedGoogle Scholar
  39. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B (1993) Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 22:1557–1563CrossRefPubMedGoogle Scholar
  40. Pillai HS, Ganapathi S (2013) Heart failure in South Asia. Curr Cardiol Rev 9:102–111CrossRefPubMedGoogle Scholar
  41. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González- Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P (2016) On behalf of Authors/task force members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975CrossRefPubMedGoogle Scholar
  42. Reddy KS, Yusuf S (1998) Emerging epidemic of cardiovascular disease in developing countries. Circulation 97:596–601CrossRefPubMedGoogle Scholar
  43. Ruwald MH, Solomon SD, Foster E, Kutyifa V, Ruwald AC, Sherazi S, McNitt S, Jons C, Moss AJ, Zareba W (2014) Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 130:2278–2286CrossRefPubMedGoogle Scholar
  44. Sakata Y, Shimokawa H (2013) Epidemiology of heart failure in Asia. Circ J 77:2209–2217CrossRefPubMedGoogle Scholar
  45. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59:442–451CrossRefPubMedGoogle Scholar
  46. Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H (2011) CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan – first report from the CHART-2 Study. Circ J 75:823–833CrossRefPubMedGoogle Scholar
  47. Shimokawa H, Miura M, Nochioka K, Sakata Y (2015) Heart failure as a general pandemic in Asia. Eur J Heart Fail 17:884–892CrossRefPubMedGoogle Scholar
  48. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S (2008) Spectrum of heart disease and risk factors in a black urban population in South Africa (the heart of Soweto study): a cohort study. Lancet 371:915–922CrossRefPubMedGoogle Scholar
  49. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP et al (2012) Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126:65–75CrossRefPubMedGoogle Scholar
  50. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 44:134–142CrossRefPubMedPubMedCentralGoogle Scholar
  51. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H (2017) CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19:1258–1269CrossRefPubMedGoogle Scholar
  52. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H (2015) CHART-2 Investigators. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan – report from the CHART Studies. Circ J 79:2396–2407CrossRefPubMedGoogle Scholar
  53. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ (2006) Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113:1966–1973CrossRefPubMedGoogle Scholar
  54. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbély A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51CrossRefPubMedGoogle Scholar
  55. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128:240–327CrossRefGoogle Scholar
  56. Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:2746–2753CrossRefPubMedGoogle Scholar
  57. Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S, Nauffal V, Marine JE, Eldadah Z, Dickfeld T, Ellenbogen KA, Tomaselli GF, Cheng A (2015) Changes in follow-up left ventricular ejection fraction associated with outcomes in primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy device recipients. J Am Coll Cardiol 66:524–531CrossRefPubMedPubMedCentralGoogle Scholar
  58. Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure—abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953–1959CrossRefPubMedGoogle Scholar
  59. Zuckerman MK, Harper KN, Barrett R, Armelagos GJ (2014) The evolution of disease: anthropological perspectives on epidemiologic transitions. Glob Health Action 7:23303CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Yasuhiko Sakata
    • 1
  • Kanako Tsuji
    • 1
  • Kotaro Nochioka
    • 1
  • Hiroaki Shimokawa
    • 1
    Email author
  1. 1.Department of Cardiovascular Medicine and Department of Evidence-based Cardiovascular MedicineTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations